Vident Investment Advisory, LLC Next Cure, Inc. Transaction History

Vident Investment Advisory, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$9.47 - $12.43 $488,983 - $641,823	-51,635 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$8.15 - $21.17 $28,052 - $72,867	-3,442 Reduced 6.25%	51,635 $454,000
Q2 2020 Jul 17, 2020	BUY	$21.19 - $40.2 $566,408 - $1.07 Million	26,730 Added 94.3%	55,077 $1.18 Million
Q1 2020 May 12, 2020	SELL	$32.32 - $58.37 $65,415 - $118,140	-2,024 Reduced 6.66%	28,347 $1.05 Million
Q4 2019 Feb 11, 2020	BUY	$25.0 - $92.22 $759,275 - $2.8 Million	30,371 New	30,371 $1.71 Million

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $21.1M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.